Nasitop (Bilastine)

Bilastine works by selectively binding to peripheral H1 receptors, preventing histamine from attaching to these sites. This blockade stops the cascade of events that cause vasodilation, increased vascular permeability, and nerve stimulation, thereby reducing typical allergic signs such as itching, swelling, and nasal discharge.

The specific dose of Nasitop is determined by the prescribing healthcare professional based on the patient’s age, condition, and overall health. In most adult cases, a single tablet taken once daily is common, but the exact regimen should follow the prescriber’s instructions and the product label.

Safety data for bilastine in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Nasitop.

To place an order, submit an enquiry on the Nasitop product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nasitop (bilastine) is a second‑generation antihistamine known for minimal sedation compared with first‑generation agents. Its selective H1 antagonism offers effective symptom control while reducing central nervous system effects, making it a preferred option for patients who need to avoid drowsiness.

Nasitop tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Nasitop is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the specific instructions provided by their prescriber or the product label for optimal absorption.

Although rare, serious adverse reactions may include anaphylaxis, severe skin reactions such as Stevens‑Johnson syndrome, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience symptoms like difficulty breathing, widespread rash, or irregular heartbeat.

Nasitop is contraindicated in individuals with known hypersensitivity to bilastine or any of the tablet’s excipients. Caution is also advised for patients with severe renal impairment, and it should be avoided in those taking medications that strongly inhibit CYP3A4 unless supervised by a healthcare professional.